Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.